EN DE
STOCK COMPARISON

Orum vs Vertex Pharmaceuticals: Fair Value & Quality

Both stocks run through our valuation models. Here is how Orum (475830) and Vertex Pharmaceuticals (VRTX) compare, as of Sep 30, 2026.

As of Sep 30, 2026, Fair Value Calculator sees Vertex Pharmaceuticals as the more attractively valued of the two: Orum trades at KRW 22,150 versus a fair value of KRW 4,518 (−79.6%), while Vertex Pharmaceuticals trades at $527 versus $580 (+10.2%).
Orum
475830.KQ · KRW · Healthcare
−79.6%
upside to fair value
overvalued
PriceKRW 22,150
Fair ValueKRW 4,518
Quality29/100
Vertex Pharmaceuticals
VRTX · USD · Health Care
+10.2%
upside to fair value
undervalued
Price$527
Fair Value$580
Quality80/100
Get comparisons like this free by email every month: the most undervalued quality stocks.

Head-to-head numbers

Green is the better side of a row, red the weaker one (for valuation multiples: lower = cheaper). Grey rows are for reference only and are not scored.

betterweakerfor reference, not scored

OrumVertex Pharmaceuticals
Valuation
n/aP/E (TTM)30.7×
n/aP/E ex one-offs (FY2025)31.3×
n/aForward P/E (FY2027)26.2×
n/aMedian P/E at FY-end (8 FY, ex one-offs where documented)25.7×
50.38×P/S (TTM)10.72×
n/aP/B7.23×
n/aEV/EBITDA25.6×
n/aPEG1.89×
−79.6%Fair value upside+10.2%
Profitability
n/aOperating margin38.1%
n/aEBIT margin trend (5Y)0.86×
-22.4%Return on equity23.5%
-14.9%Return on assets11.9%
Growth
-77.5%Revenue growth (YoY)12.5%
-32.3%Avg. growth/yr (3Y)10.6%
n/aAvg. growth/yr (5Y)14.2%
n/aValue creation/yr+13.5%
Balance & size
n/aInterest coverage (EBIT/interest)357.9×
0.01×Debt / equity0.03×
$1BMarket cap$135B
weakGrowth qualityhealthy
The P/E excluding one-off items is only shown where the special items are documented in the accounts (our own raw data or SEC filings). If one side lacks it, the reported P/E stays scored.
Vertex Pharmaceuticals, median P/E at fiscal year-end, 8 fiscal years (2017 to 2025), reported earnings, 5 of the years ex one-offs: 25.7.
Forward P/E: price divided by the analyst consensus for the first fiscal year that has not started yet. The current year carries special items from quarters already reported.
Valuation multiples (P/E, P/S, P/B, EV/EBITDA) are shown but not scored here: the two companies sit in different sectors, and multiples only compare fairly between similar business models. PEG stays scored, as it relates the P/E to growth.

Vertex Pharmaceuticals leads: 1 to 4 metric wins.

n/a = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Orumof which business quality 29 · market factors 10 Vertex Pharmaceuticalsof which business quality 78 · market factors 74
ProfitabilityMargins and returns on capital today
0
72
Quality GrowthAre margins and returns improving?
13
65
CashflowEarnings quality: real cash, not paper profit
8
79
Fin. StrengthBalance sheet, leverage, solvency risk
77
92
InvestmentDisciplined investing over empire-building
0
58
Low VolatilityCalm price path (market factor)
0
85
MomentumPrice trend over the last 3–12 months (market factor)
24
65
52W MomentumDistance to the 52-week high (market factor)
0
78
Net IssuanceShare count: buybacks or dilution?
74
89

What the models say

How far the median fair value (base case) per model family sits from the current price, in percent. The amount in the currency of the trading venue is shown underneath.

above the price, more than 15% above close to the price, 85% to 115% of the price below the price, more than 15% below

Model familyOrumPrice KRW 22,150Vertex PharmaceuticalsPrice $527
DCF Modelsn/a−13.9%close to the price$454
Earnings-Basedn/a−1.9%close to the price$517
Multiplesn/a−47.1%below the price$279
Asset-Based−81.4%below the priceKRW 4,130−90.6%below the price$49.34
Growth DCFn/a−33.7%below the price$349
Economic Profitn/a−53.5%below the price$245
Growth Earningsn/a+31.6%above the price$693
Minimum−81.4%below the priceKRW 4,130−90.6%below the price$49.34
Maximum−81.4%below the priceKRW 4,130+31.6%above the price$693
Median−81.4%below the priceKRW 4,130−33.7%below the price$349
Geometric mean−81.4%below the priceKRW 4,130−44.1%below the price$294

Minimum, maximum, median and geometric mean refer to the family values in this table. Geometric because deviations are ratios: half the price and twice the price average to 100%, not 125%.

Orum: 1 of 1 models see the stock below the current price.

Vertex Pharmaceuticals: 19 of 24 models see the stock below the current price.

Scenario ranges

From our cautious bear scenario to the optimistic bull scenario. The white tick is the current price (value above it), the green tick the fair value (value below it): if the price sits left of the fair value, there is room to rise.

Orum
Price KRW 22,150
Fair Value KRW 4,518
Bear KRW 2,982Bull KRW 5,648
Vertex Pharmaceuticals
Price $527
Fair Value $580
Bear $348Bull $1,257

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Orum · Healthcare

Quality score29 · bottom 25%
Fair value upside−79.6% · bottom 25%

Vertex Pharmaceuticals · Health Care

Quality score80 · Top 25%
Fair value upside+10.2% · above median

Bottom line

As of Sep 30, 2026, Fair Value Calculator sees Vertex Pharmaceuticals as the more attractively valued of the two: Orum trades at KRW 22,150 versus a fair value of KRW 4,518 (−79.6%), while Vertex Pharmaceuticals trades at $527 versus $580 (+10.2%).

Vertex Pharmaceuticals has the higher quality score (80/100).

Open Vertex Pharmaceuticals live analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 26 models. Values change with price and fundamentals; the date shown above applies.